AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17729021
Drug: Duloxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30 or 60 mg daily for the first week, followed by 60, 90, or 120 mg daily for up to 11 weeks)
Trial: 14642083
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg bid plus amoxicillin 1000mg bid and levofloxacin 200mg bid
Trial: 8545281
Drug: estramustine phosphate
RxNorm normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estramustine phosphate 600 mg/m2‐po daily for up to 2 years
Trial: 8545281
Drug: adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjuvant therapy (any)
Trial: 1678550
Drug: SKF-94482 400
RxNorm normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKF-94482 400 mg at 0830 h
Trial: 1678550
Drug: SKF-94482 400
RxNorm normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKF-94482 400 mg at 1830 h
Trial: 1678550
Drug: SKF-94482 200
RxNorm normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKF-94482 200 mg or 300 mg at 0830 and 1830 h
Trial: 634895
Drug: Pethidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (50 mg intravenously)
Trial: 27710241
Drug: Combination AI/GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination AI/GH
Trial: 24423356
Drug: Testosterone and
RxNorm normalized name: testosterone and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone and growth hormone (n = 17)
Trial: 20047544
Drug: Single-dose azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose azithromycin (30 mg/kg as a single dose)
Trial: 20047544
Drug: Amoxycillin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (50 mg/kg/day in two divided doses for a minimum of 7 days)
Trial: 12860945
Drug: Lanreotide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide (1 mg three times a day administered subcutaneously)
Trial: 12860945
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lanreotide and interferon alfa
Trial: 11310381
Drug: Intradermal HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal HBV vaccine (20 mu gms) once a week for 6 weeks
Trial: 11310381
Drug: Intradermal HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal HBV vaccine (20 mu gms) twice a week for 6 weeks
Trial: 11310381
Drug: Epo and
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epo and twice weekly vaccine (group 2 of phase 2)
Trial: 6643397
Drug: Natural history
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural history control (no immediate treatment)
Trial: 21949007
Drug: tocilizumab 8
RxNorm normalized name: tocilizumab 80 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tocilizumab 8 mg/kg every 4 weeks
Trial: 16286056
Drug: Rimantadine 100
RxNorm normalized name: riMANTAdine 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimantadine 100 mg once daily for 14 days (for influenza A) or placebo (for influenza B)
Trial: 10391957
Drug: IgG antibody
RxNorm normalized name: CM1 IgG antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibody levels against 38 kDa mycobacterial antigen (measured using ELISA based kits)
Trial: 7543113
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg testosterone buciclate (TB) injection
Trial: 7543113
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg testosterone buciclate (TB) injection
Trial: 7543113
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (600 mg and 1200 mg TB)
Trial: 2702967
Drug: Weekly pedometer
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly pedometer distance
Trial: 946937
Drug: Low-lactose skim
RxNorm normalized name: skim milk
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-lactose skim milk (15 g lactose, 2.5 cups)
Trial: 946937
Drug: Low-lactose skim
RxNorm normalized name: skim milk
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-lactose skim milk (7.5 g lactose, 2.5 cups)
Trial: 946937
Drug: Regular skim
RxNorm normalized name: skim milk
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular skim milk (30 g lactose, 2.5 cups)
Trial: 946937
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g lactose in water (250 ml)
Trial: 946937
Drug: Skim milk
RxNorm normalized name: skim milk
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skim milk (500 ml) with 25 g lactose
Trial: 946937
Drug: Whole milk
RxNorm normalized name: Calcium fortified whole milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole milk (500 ml) with 25 g lactose
Trial: 946937
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g lactose in lactose-reduced skim (500 ml)
Trial: 946937
Drug: Whole milk
RxNorm normalized name: Calcium fortified whole milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole milk (500 ml) with 10 g lactose
Trial: 31404466
Drug: 1-week nicotine
RxNorm normalized name: nicotine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week nicotine replacement therapy sample (NRTS) including gum/patch and brief advice lasting 10 minutes
Trial: 31422079
Drug: Long-term proton
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term proton pump inhibitors (PPIs) therapy (>12 months, n = 85)
Trial: 31422079
Drug: No proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No proton pump inhibitors (non-PPI group, n = 118)
Trial: 28358634
Drug: Alfaxalone 3
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone 3 mg/kg IV
Trial: 28358634
Drug: Alfaxalone 5
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone 5 mg/kg IV
Trial: 28358634
Drug: Alfaxalone 10
RxNorm normalized name: alfaxalone 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone 10 mg/kg IV
Trial: 23631544
Drug: Psychoanalytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoanalytic therapy (mean duration: 39 months, mean dose: 234 sessions)
Trial: 23631544
Drug: Psychodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic therapy (mean duration: 34 months, mean dose: 88 sessions)
Trial: 22987495
Drug: Psychoanalytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoanalytic therapy
Trial: 8075874
Drug: maxEPA (eicosapentaenoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maxEPA (eicosapentaenoic acid 0.178 g g‐1; docosahexaenoic acid 0.116 g g‐1) capsules 10 g per day for 28 days
Trial: 2583158
Drug: Caffeinated drink
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated drink at a dose of 5 mg.kg‐1 body mass and at the 3rd and 5th h of marching an additional drink at a dose of 2.5 mg.kg‐1 body mass
Trial: 28282221
Drug: Microfracture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfracture with collagen augmentation (group 2)
Trial: 26485914
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (control) with methotrexate (MTX) and prednisone for 6 months
Trial: 10381799
Drug: EMD 61753
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 61753 (10 mg p.o.)
Trial: 10381799
Drug: EMD 61753
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 61753 (0.1‐3.2 mg i.pl.)
Trial: 10381799
Drug: EMD 61753
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 61753 (1.6 mg)
Trial: 9007598
Drug: Meropenem monotherapy
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem monotherapy (1 g intravenously every 8 hours)
Trial: 9007598
Drug: Cefotaxime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (2 g every 8 hours) plus metronidazole (0.5 g intravenously every 8 hours) for 5 to 10 days
Trial: 9007598
Drug: Cefotaxime/metronidazole combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime/metronidazole combination
Trial: 1645622
Drug: Etoposide 350
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 350 mg/m2
Trial: 1645622
Drug: Etoposide 370
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 370 mg/m2
Trial: 1645622
Drug: Etoposide (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (dose range 330-370 mg/m2)
Trial: 1645622
Drug: Etoposide (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (dose > 300 mg/m2)
Trial: 7016157
Drug: Oral misonidazole
RxNorm normalized name: metronidazole Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral misonidazole at a dose of 3 g/m2 preceding each of 4 weekly radiation doses
Trial: 31547939
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium bicarbonate solution
Trial: 31547939
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline solution
Trial: 22247354
Drug: Ocrelizumab (OCR)
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab (OCR) 50 mg
Trial: 22247354
Drug: Ocrelizumab (OCR)
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab (OCR) 200 mg
Trial: 22247354
Drug: Ocrelizumab (OCR)
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab (OCR) 500 mg
Trial: 20085455
Drug: FKD peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FKD peptide and p(S/T)F antibody
Trial: 16857266
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (COMB)
Trial: 16857266
Drug: Medication side-effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication side-effects
Trial: 8786596
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic at 42 degrees C (amethocaine 1%)
Trial: 8786596
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic at 42 degrees C (oxybuprocaine 0.4%)
Trial: 8786596
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic at 42 degrees C (lignocaine 4%)
Trial: 8786596
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic at room temperature (amethocaine 1%)
Trial: 8786596
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic at room temperature (oxybuprocaine 0.4%)
Trial: 8786596
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic at room temperature (lignocaine 4%)
Trial: 3177196
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Metoprolol + Nifedipine)
Trial: 30638411
Drug: Raft-forming chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raft-forming chewable tablets containing Nizatidine
Trial: 30638411
Drug: Optimized formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized formulations using sodium alginate, calcium carbonate, and sodium bicarbonate
Trial: 26026350
Drug: Dipyrone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone (25 mg/kg)
Trial: 26026350
Drug: Meloxicam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (0.2 mg/kg)
Trial: 26026350
Drug: Dipyrone-Meloxicam (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone-Meloxicam (25 mg/kg and 0.2 mg/kg, respectively)
Trial: 21236452
Drug: 1 ED(95)
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ED(95) of rocuronium (0.3 mg/kg)
Trial: 11827684
Drug: Human urotensin
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human urotensin II (hUII) infusion at doses of 100 and 300 pmol min(‐1)
Trial: 11827684
Drug: Human urotensin
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human urotensin II (hUII) infusion with nitric oxide clamp
Trial: 11827684
Drug: Local administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local administration of hUII (3‐300 pmol min(‐1))
Trial: 9881390
Drug: Leucocyte-depleting filter
RxNorm normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte-depleting filter (group L, n = 20)
Trial: 7979954
Drug: PGG-glucan at
RxNorm normalized name: B-glucan PGG
DrugBank: Odetiglucan (DB17468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGG-glucan at a dose of 0.1 mg/kg
Trial: 7979954
Drug: PGG-glucan at
RxNorm normalized name: B-glucan PGG
DrugBank: Odetiglucan (DB17468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGG-glucan at a high dose (1.0 mg/kg or 2.0 mg/kg)
Trial: 3377942
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl (TTS-fentanyl)
Trial: 29630034
Drug: IV DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV DEX 2.0 μg/kg
Trial: 14993489
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (10-150 microg) administered once a week or once every 2 weeks
Trial: 14993489
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (for subjects with baseline haemoglobin < 11 g/dl)
Trial: 11641677
Drug: Vaginally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginally administered misoprostol (25 microg)
Trial: 11641677
Drug: Oral plus
RxNorm normalized name: Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride 500 MG-3 MG-60 MG Oral Tablet, Extended Release [DRIXORAL PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral plus vaginal misoprostol (25 microg orally, 25 microg vaginally)
Trial: 11641677
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (25 microg)
Trial: 9695781
Drug: Live tularemia
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live tularemia vaccine (LTV) immunization 15-20 days before surgery
Trial: 7723271
Drug: Immunomodulation agents
RxNorm normalized name: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulation agents
Trial: 30309389
Drug: PQ912 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PQ912 800 mg bid for 12 weeks
Trial: 28809743
Drug: Asunaprevir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asunaprevir (100 mg twice daily) + Daclatasvir (60 mg once daily) for 24 weeks
Trial: 23121459
Drug: Thermo-reversible sustained-release
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermo-reversible sustained-release green tea catechin gel
Trial: 21515474
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of dexmedetomidine at 0.2 µg·kg(‐1)·h(‐1)
Trial: 18435868
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV (types 6/11/16/18) L1 virus‐like‐particle vaccine
Trial: 16950199
Drug: Aspirin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (all dosing regimes)
Trial: 12969017
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori infection (no treatment prior to end of follow-up)
Trial: 8684767
Drug: Microcolposcopy before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcolposcopy before excisional treatment
Trial: 1853617
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) treatment (250 mg daily) for 3 months starting from the seventh postoperative day
Trial: 1853617
Drug: No ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ASA treatment (control group)
Trial: 6603042
Drug: Co-trimoxazole, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole, 2 tabs twice a day for 14 days
Trial: 6603042
Drug: Trimethoprim, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim, 250 mg twice a day for 14 days
Trial: 17222649
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg zinc
Trial: 15583956
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg budipine (t.i.d.)
Trial: 10066843
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (rtPA and placebo)
Trial: 2292534
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil 200 mg bd orally for 10 days
Trial: 2292534
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g daily im for 10 days
Trial: 6789356
Drug: Pentobarbital (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital (three doses)
Trial: 29741201
Drug: Fermented Papaya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented Papaya Preparation (FPP®) 9g/day
Trial: 25492830
Drug: Amiloride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (5 mg/d, increased to 10 mg if BP control not achieved at 4 weeks)
Trial: 22571202
Drug: Lenalidomide maintenance
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide maintenance therapy (10 mg per day for the first 3 months, increased to 15 mg if tolerated)
Trial: 20821979
Drug: Reamberin (antioxidant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reamberin (antioxidant preparation)
Trial: 1563213
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of furosemide (4 mg/hr for 8 hours after an 8 mg loading dose, total dose 40 mg)
Trial: 1563213
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of furosemide (40 mg)
Trial: 1563213
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of furosemide
Trial: 1563213
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of furosemide
Trial: 3890435
Drug: Indoprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoprofen (400 mg, intravenous)
Trial: 3890435
Drug: Oxicone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxicone (10 mg, intramuscular) combined with papaverine (20 mg)
Trial: 3890435
Drug: Oxicone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxicone (10 mg, intramuscular)
Trial: 3013766
Drug: Nadolol, 80
RxNorm normalized name: Nadolol, 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol, 80 mg/day plus hydrochlorothiazide 12.5 mg/day
Trial: 3013766
Drug: Nadolol, 80
RxNorm normalized name: Nadolol, 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol, 80 mg/day plus hydrochlorothiazide 25 mg/day